IP Library Granted Patent US 12697323
Granted Patent B2
US 12697323 · App. 18/295,616 · Granted Aug 4, 2026

Implantable isoxazoline pharmaceutical compositions and uses thereof

Inventors: Keith Freehauf (Stockton, NJ); Anagha Avinash Bhakay (Fanwood, NJ)
Assignee: Intervet Inc.
A61K31/42A61K9/0024A61K9/1623A61K9/1635A61K9/1641A61K9/2081A61K9/5031A61K47/02A61K47/10A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697323
App. No.
18/295,616
Granted
Aug 4, 2026
Kind
B2
Abstract

An implant for the control of parasites in livestock comprising an isoxazoline compound of Formula (I) or salt or solvate thereof, wherein the implant comprises one or more pellets each of which comprises the isoxaxoline compound and a pharmaceutically acceptable excipient and a method of preventing or treating a parasite infestation using the same.

Claims (20)

1 . A method of treating a parasite infestation in livestock animals comprising administering an implant to animals in need thereof wherein the implant comprises

one or more immediate release pellets and one or more delayed release pellets, wherein the ratio of the immediate release pellets and the delayed release pellets is between 1:10 and 10:1 and wherein

a) the immediate release pellets comprise

i) fluralaner

ii) diluent;

iii) binder and

iv) micronized intragranular poloxamer, and

b) the delayed release pellets comprise

i) fluralaner

ii) diluent, and

iii) binder;

wherein the delayed release pellets are coated with a biodegradable polymer.

2 . The method of claim 1 , wherein the implant is effective for at least 3 months.

3 . The method of claim 1 , wherein the diluent is lactose.

4 . The method of claim 1 , wherein the binder is povidone.

5 . The method of claim 1 , wherein the percentage of fluralaner in each pellet is between about 50% w/w to about 90% w/w.

6 . The method of claim 1 , wherein the ratio of the immediate release pellets to delayed release pellets is about 1:1.

7 . The method of claim 1 , wherein the biodegradable polymer is chosen from poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL).

8 . The method of claim 1 , wherein the biodegradable polymer is poly(lactic-co-glycolic acid) (PLGA) and the ratio of the lactic acid and glycolic acid monomers in the PLGA is about 50:50 to about 90:10.

9 . The method of claim 1 , wherein the delayed release pellets are coated with PLGA 65:35.